Franca, i think you meant to say $20 plus by May 27th. I think you you will find most analystswould agree that with approval $60-100 is more likely by end of year. Unlike other medications coming to market we already have a built in market already worth billions. This is a wholly unique opportunity that doesn’t come around very often if ever
seanearling10
Posts
-
-
Saltytimtation- off label gets no protection. The new medication will be pure and of standardized strength/potency. There will be no one wiling to compound off-label because of patent infringement. No providers will write off label for fear of medical malpractice. Insurance companies will not pay for it or insure providers that write it. To put it simple that even with the price increase.… this will be the cheapest and safest treatment available. Compounding off label will no longer exist which means 100% capture of that market.
-
Old news and already built into the price.
-
Frank, you selling short only creates shares you will have to cover later. When you are done in the kiddy sand box.… come play with the real investors. Price doesn't reflect value at this time.
-
The current price does not reflect its value. It is simply a reflection of daytraders and shorts upon the approval of EMA revenue will begin to be produced and an entirely different class of investor will be coming to the stock. Which point price corrections will begin to accelerate forward based on prebuilt market, and future revenues.
-
Syntone Ventures LLC is a major pharma distributor in the EU……just a little foreshadowing of things to come!
-
Waldo_III, that is your dumbest post yet. Hard to treat you like an experienced investor.
-
Frank, you keep saying garbage, but after all these years, you’re still here try to explain that one to us
-
Frank ~ go educate yourself. No one wants to read your outlandish statements. we prefer to deal with people that work in facts.
-
Just another day of shorts selling to shorts. True ling investors have not lost any money. True longs don't gamble on emotional daily swings. The real money is in bringing this product to market. Today's price diesnotvreforct the real value. Be patient and hold, approval is only days away.
-
I just bought me some more shares from a crazy short. I sure love getting good deals.
-
Isn't interesting how the shorts can always find a buyer at this price. I wonder if they think there will be sellers when the EU approval comes in a few days… like France Chance said it will be a lot of easy money for the longs. Sorry shorts you arecraking one to many rounds on the dance floor. You are going to play the fiddler his due.
-
Mbappe, the only problem with 10% market capture is that it doesn't factor in market exclusivity. Upon approval all off label must stop due to patent exclusivity. Simply put patients can convert or go blind. I don't know pricing but believe the increase in price will still leave this the least approved therapy on market. I believe 100% of compounding business will be captured
-
Frank Chance, you are a long way from th$7.00 short sale. Get out before you lose your house. Pride is going to cost you dearly here. Just admit you got this one wrong.
-
Bernie Forrester, future revenue should cap out at about $200-300 a share with current market information. There is about another year and a half to wait. Patience is a virtue.
-
Brad, I like your thinking. I think you are conservatively low on sales for EU. The US will be a much larger market mid to late 2025. Price resistance will be all but nil. It will still be the least expensive and safest medicine on market with regulatory approval. Remember failure to treat will lead to blindness.
-
Angelo Dilanni I have been in Pharma for over 25 years and have never seen a cleaner application than Otlk for approval in Europe. superior safety, and efficacy study already done Norse 2 and the National Eye Institute CATT study done in 2005. The current FDA required study is a CATT repeat study so statistically the outcome is already known. Not to mention almost two decades of off-label use of this compound makes this a very established form of treatment(if the was a problem, we would already know).These approvals would finally give EMA and FDA regulatory control of this therapy. There is no company debt and way more money than needed to manufacture and market. The only question left is, did they resolve the CMC issues and this would only slow the process not stop it. It should be noted there has been plenty of time to resolve any FDA issues.
-
Tick, tock, tick, tock, the music is about to stop! He devil is about to collect his due. The day trading short are about to pay a fortune for the few actual stocks being traded. Recycled short sales are going to dry up. Who will get out and who will get stuck? I'm going to go start the popcorn.
-
Frank Chance is back. He is talking like he is worried…… he should be!
-
Derek Danial, you may want to get a broker to help you. Based on all your statements… I don't think you have a clue what's going on or how things are done. My advice is done go to deep on your first trades and maybe pick up some educational books on trading. Last tip: font listen to The Wiz, Waldo_III or Frank Chance. Clueless doesn't begin to describe their insight on stocks.
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK
OTLK